Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 511 participants.

Also called NCT01984424

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 511 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01984424
  • EudraCT 2013-000935-29
Other papers using this trial's data
  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial JAMA, 2016-04-19 DOI, PubMed 27039291

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Czechia, Denmark, France, Germany, Italy, Netherlands, New Zealand, Norway, South Africa, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01984424. Randomized; quadruple masking; primary purpose treatment. Start 2013-12-10 (actual); primary completion 2015-11-10 (actual). Results posted on 2018-03-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Acronym
GAUSS-3
Condition
Hyperlipidemia
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Placebo to Atorvastatin
Intervention (Other)
Placebo to Ezetimibe
Intervention (Drug)
Ezetimibe
Intervention (Other)
Placebo to Evolocumab
Intervention (Drug)
Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01984424
Content hash
371377ec3614db85174a4d9797439a6f6d6711c0754fbfad028239addc81f57c